Drug: Technivie (TEK-ni-vee)
- Ombitasvir (NS5A inhibitor)
- Paritaprevir (protease inhibitor)/ritonavir (protease inhibitor)
Technivie is taken twice a day with ribavirin with food. The treatment duration is 12 weeks.
The overall cure rates of Technivie is 91% to 100%. The wholesale acquisition cost (WAC) for a 12-week treatment course of Technivie is $76, 653. It is taken for 12 weeks based on clinical trial data submitted to the FDA.
Patient Assistance Program: There are no patient assistance programs listed on the AbbVie website for Technivie.
Common Drug Interactions: The herb St. John’s wort should be avoided. Talk to your medical provider about any medications, supplements, herbs or over-the-counter medications you are taking to prevent any possible problems that may interfere with how well Technivie will work.
See the Highlights of Prescribing Information for a complete listing of drug interactions.
Note: The Food and Drug Administration (FDA) is requiring that hepatitis C (HCV) medication guides (package inserts) list a warning about a possible risk of hepatitis B (HBV) reactivation while on HCV antiviral therapy. Reactivation of HBV can cause possible liver damage. However, the risk is extremely rare. The reactivation has been reported with interferon and direct-acting antiviral medications.
Patients should talk to their medical providers about the hepatitis B tests and vaccination prior to starting HCV treatment.
Side Effects: The most common side effects of Technivie plus ribavirin that occurred in more than 5% of patients included asthenia (feeling weak or lack of energy) fatigue, nausea, insomnia (sleep problems), pruritus (itching), other types of skin reactions.
Pregnancy: There are no studies of Technivie in pregnant women. Ribavirin can cause birth defects and miscarriages. If you are a male taking ribavirin you and your female sexual partner must use two types of effective birth control. Your female sexual partner will have to take a pregnancy test before and during treatment and 6 months after treatment ends. If you are a female taking ribavirin you and your male sexual partner must use two types of effective birth control. You will also have to take a pregnancy test before, during and 6 months after treatment ends.
Pediatric Patients: Technivie is not approved to treat pediatric patients. Clinical studies are on-going.
HIV/HCV Coinfection: The same dosage recommendation for people who are coinfected with HIV and hepatitis C are as those who are monoinfected with HCV. Careful attention should be given to potential drug-drug interactions to HIV antiviral drugs. Ritonavir is also an HIV-1 protease inhibitor. People who are coinfected with HIV and hepatitis C should also be on a HIV regime to prevent a potential “protease inhibitor drug resistance.”
Recommended Treatment Duration – Cure Rate
|Patient Characteristics||Medications/Duration||Cure Rate|
|Genotype 4, with compensated cirrhosis and without cirrhosis||Technivie/ribavirin* 12 weeks||91% to 100%|
*Technivie can be taken without ribavirin in patients who are treatment naïve (never been treated) and who cannot tolerate ribavirin.
Commonly used termsShare This Page